SNDX
Syndax Pharmaceuticals, Inc.$18.13+0.22 (+1.23%)Prev Close$17.91·MCap$1.56B·P/E—·Vol763.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
13
$5.94M
◆
Net Activity
Net Seller
$5.94M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Syndax Pharmaceuticals, Inc. (SNDX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 13 insider sales totaling $5.94M. The most recent insider transaction was by Botwood Nicholas A.J. (officer: Head of R&D, CMO), who sold $1.18M worth of shares on Jun 12, 2026. Syndax Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.56B.
SNDX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Botwood Nicholas A.J. | officer: Head of R&D, CMO | Sell | 65,515 | $18.07 | $1.18M | 60,885-52% |
| Jun 2, 2026 | Metzger Michael A | director, officer: Chief Executive Officer | Sell | 6,847 | $18.99 | $130.0K | 484,843 |
| Jun 2, 2026 | Goldan Keith A. | officer: Chief Financial Officer | Sell | 1,177 | $18.99 | $22.4K | 139,252 |
| Feb 10, 2026 | Metzger Michael A | director, officer: Chief Executive Officer | Sell | 17,159 | $21.03 | $360.8K | 491,690 |
| Feb 10, 2026 | Goldan Keith A. | officer: Chief Financial Officer | Sell | 3,410 | $21.03 | $71.7K | 140,429 |
| Feb 9, 2026 | Metzger Michael A | Chief Executive Officer | Sell | 17,159 | $21.03 | $360.8K | 0 |
| Feb 9, 2026 | Goldan Keith A. | Chief Financial Officer | Sell | 3,410 | $21.03 | $71.7K | 0 |
| Feb 4, 2026 | Goldan Keith A. | Chief Financial Officer | Sell | 2,082 | $20.62 | $42.9K | 0 |
| Feb 4, 2026 | Metzger Michael A | Chief Executive Officer | Sell | 7,412 | $20.62 | $152.8K | 0 |
| Sep 8, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 157,307 | $16.41 | $2.58M | 0 |
| Aug 14, 2025 | Podlesak Dennis | Director | Sell | 57,600 | $15.19 | $875.1K | 0 |
| Jul 16, 2025 | Goldan Keith A. | Chief Financial Officer | Sell | 1,296 | $9.29 | $12.0K | 0 |
| Jul 16, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 7,534 | $9.29 | $70.0K | 0 |
| May 19, 2025 | Huber Martin H. Jr. | Director | Buy | 5,000 | $8.99 | $45.0K | 0 |
| May 19, 2025 | Katkin Keith | Director | Buy | 10,000 | $9.11 | $91.1K | 0 |
| May 16, 2025 | Botwood Nicholas A.J. | Head of R&D, CMO | Buy | 11,765 | $8.99 | $105.8K | 0 |
| Mar 4, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 7,814 | $15.05 | $117.6K | 0 |
| Feb 12, 2025 | Gallagher Neil | President, Head of R&D | Sell | 4,618 | $15.50 | $71.6K | 85,095 |
| Feb 12, 2025 | Goldan Keith A. | Chief Financial Officer | Sell | 3,777 | $15.50 | $58.6K | 90,746 |
| Feb 12, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 13,288 | $15.50 | $206.0K | 300,121 |
| Jun 17, 2024 | Goldan Keith A. | Chief Financial Officer | Buy | 1,250 | $20.03 | $25.0K | 52,623 |
| Aug 10, 2023 | Morrison Briggs | Sell | 52,855 | $18.27 | $965.4K | 17,836-75% | |
| Aug 3, 2023 | Meury William | Sell | 83,000 | $20.46 | $1.70M | 48,000-63% | |
| Jul 11, 2023 | Morrison Briggs | Sell | 52,855 | $20.40 | $1.08M | 17,836-75% | |
| Jun 14, 2023 | Goldan Keith A. | Chief Financial Officer | Sell | 577 | $22.31 | $12.9K | 2,628 |
| Jun 9, 2023 | Morrison Briggs | Sell | 52,855 | $21.18 | $1.12M | 46,109-53% | |
| May 10, 2023 | Morrison Briggs | Sell | 52,855 | $21.41 | $1.13M | 17,836-75% | |
| Apr 12, 2023 | Morrison Briggs | Sell | 52,855 | $19.53 | $1.03M | 17,836-75% | |
| Mar 14, 2023 | Morrison Briggs | President, Head of R&D | Sell | 52,854 | $22.53 | $1.19M | 17,836-75% |
| Feb 17, 2023 | Ordentlich Peter | Chief Scientific Officer | Sell | 25,000 | $25.84 | $646.1K | 0Exit |
| Feb 8, 2023 | Metzger Michael A | Chief Executive Officer | Sell | 5,959 | $27.64 | $164.7K | 17,659-25% |
| Feb 8, 2023 | Morrison Briggs | President, Head of R&D | Sell | 52,854 | $26.83 | $1.42M | 17,836-75% |
| Feb 3, 2023 | Ordentlich Peter | Chief Scientific Officer | Sell | 69 | $28.43 | $2.0K | 0Exit |
| Jan 13, 2023 | Legault Pierre | Sell | 39,000 | $26.84 | $1.05M | 32,000-55% | |
| Dec 2, 2022 | Ordentlich Peter | Chief Scientific Officer | Sell | 25,000 | $25.04 | $626.0K | 265-99% |
| Oct 7, 2022 | Katkin Keith | Sell | 29,899 | $25.90 | $774.4K | 32,000-48% | |
| Oct 7, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 16,231 | $25.29 | $410.5K | 17,659-48% |
| Oct 4, 2022 | Katkin Keith | Sell | 4,101 | $25.06 | $102.8K | 32,000 | |
| Oct 4, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 33,769 | $25.02 | $844.9K | 17,659-66% |
| Sep 21, 2022 | Morrison Briggs | President, Head of R&D | Sell | 173,988 | $23.11 | $4.02M | 17,836-91% |
| Sep 16, 2022 | Morrison Briggs | President, Head of R&D | Sell | 279,420 | $23.64 | $6.60M | 17,836-94% |
| Sep 16, 2022 | Podlesak Dennis | Sell | 78,815 | $24.08 | $1.90M | 75,763-51% | |
| Aug 26, 2022 | Ordentlich Peter | Chief Scientific Officer | Sell | 25,000 | $25.04 | $625.9K | 265-99% |
| Aug 9, 2022 | Legault Pierre | Sell | 24,000 | $23.02 | $552.4K | 32,000-43% | |
| Jul 27, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 31,602 | $21.06 | $665.4K | 17,659-64% |
| Jul 8, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 15,109 | $21.07 | $318.4K | 17,659-46% |
| Jul 5, 2022 | Morrison Briggs | President, Head of R&D | Sell | 62,292 | $19.00 | $1.18M | 17,836-78% |
| Apr 5, 2022 | Morrison Briggs | President, Head of R&D | Sell | 104,173 | $17.48 | $1.82M | 42,336-71% |
| Feb 3, 2022 | Nolte Alexander | Chief Accounting Officer | Sell | 968 | $16.65 | $16.1K | 0Exit |
| Feb 3, 2022 | Ordentlich Peter | Chief Scientific Officer | Sell | 1,412 | $16.65 | $23.5K | 0Exit |
Showing 1–50 of 65
1 / 2
SNDX Insider Buying Activity
The following table shows recent insider purchases of Syndax Pharmaceuticals, Inc. (SNDX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 19, 2025 | Huber Martin H. Jr. | Director | Buy | 5,000 | $8.99 | $45.0K | 0 |
| May 19, 2025 | Katkin Keith | Director | Buy | 10,000 | $9.11 | $91.1K | 0 |
| May 16, 2025 | Botwood Nicholas A.J. | Head of R&D, CMO | Buy | 11,765 | $8.99 | $105.8K | 0 |
| Jun 17, 2024 | Goldan Keith A. | Chief Financial Officer | Buy | 1,250 | $20.03 | $25.0K | 52,623 |
SNDX Insider Selling Activity
The following table shows recent insider sales of Syndax Pharmaceuticals, Inc. (SNDX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Botwood Nicholas A.J. | officer: Head of R&D, CMO | Sell | 65,515 | $18.07 | $1.18M | 60,885-52% |
| Jun 2, 2026 | Metzger Michael A | director, officer: Chief Executive Officer | Sell | 6,847 | $18.99 | $130.0K | 484,843 |
| Jun 2, 2026 | Goldan Keith A. | officer: Chief Financial Officer | Sell | 1,177 | $18.99 | $22.4K | 139,252 |
| Feb 10, 2026 | Metzger Michael A | director, officer: Chief Executive Officer | Sell | 17,159 | $21.03 | $360.8K | 491,690 |
| Feb 10, 2026 | Goldan Keith A. | officer: Chief Financial Officer | Sell | 3,410 | $21.03 | $71.7K | 140,429 |
| Feb 9, 2026 | Metzger Michael A | Chief Executive Officer | Sell | 17,159 | $21.03 | $360.8K | 0 |
| Feb 9, 2026 | Goldan Keith A. | Chief Financial Officer | Sell | 3,410 | $21.03 | $71.7K | 0 |
| Feb 4, 2026 | Goldan Keith A. | Chief Financial Officer | Sell | 2,082 | $20.62 | $42.9K | 0 |
| Feb 4, 2026 | Metzger Michael A | Chief Executive Officer | Sell | 7,412 | $20.62 | $152.8K | 0 |
| Sep 8, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 157,307 | $16.41 | $2.58M | 0 |
| Aug 14, 2025 | Podlesak Dennis | Director | Sell | 57,600 | $15.19 | $875.1K | 0 |
| Jul 16, 2025 | Goldan Keith A. | Chief Financial Officer | Sell | 1,296 | $9.29 | $12.0K | 0 |
| Jul 16, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 7,534 | $9.29 | $70.0K | 0 |
| Mar 4, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 7,814 | $15.05 | $117.6K | 0 |
| Feb 12, 2025 | Gallagher Neil | President, Head of R&D | Sell | 4,618 | $15.50 | $71.6K | 85,095 |
| Feb 12, 2025 | Goldan Keith A. | Chief Financial Officer | Sell | 3,777 | $15.50 | $58.6K | 90,746 |
| Feb 12, 2025 | Metzger Michael A | Chief Executive Officer | Sell | 13,288 | $15.50 | $206.0K | 300,121 |
| Aug 10, 2023 | Morrison Briggs | Sell | 52,855 | $18.27 | $965.4K | 17,836-75% | |
| Aug 3, 2023 | Meury William | Sell | 83,000 | $20.46 | $1.70M | 48,000-63% | |
| Jul 11, 2023 | Morrison Briggs | Sell | 52,855 | $20.40 | $1.08M | 17,836-75% | |
| Jun 14, 2023 | Goldan Keith A. | Chief Financial Officer | Sell | 577 | $22.31 | $12.9K | 2,628 |
| Jun 9, 2023 | Morrison Briggs | Sell | 52,855 | $21.18 | $1.12M | 46,109-53% | |
| May 10, 2023 | Morrison Briggs | Sell | 52,855 | $21.41 | $1.13M | 17,836-75% | |
| Apr 12, 2023 | Morrison Briggs | Sell | 52,855 | $19.53 | $1.03M | 17,836-75% | |
| Mar 14, 2023 | Morrison Briggs | President, Head of R&D | Sell | 52,854 | $22.53 | $1.19M | 17,836-75% |
| Feb 17, 2023 | Ordentlich Peter | Chief Scientific Officer | Sell | 25,000 | $25.84 | $646.1K | 0Exit |
| Feb 8, 2023 | Metzger Michael A | Chief Executive Officer | Sell | 5,959 | $27.64 | $164.7K | 17,659-25% |
| Feb 8, 2023 | Morrison Briggs | President, Head of R&D | Sell | 52,854 | $26.83 | $1.42M | 17,836-75% |
| Feb 3, 2023 | Ordentlich Peter | Chief Scientific Officer | Sell | 69 | $28.43 | $2.0K | 0Exit |
| Jan 13, 2023 | Legault Pierre | Sell | 39,000 | $26.84 | $1.05M | 32,000-55% | |
| Dec 2, 2022 | Ordentlich Peter | Chief Scientific Officer | Sell | 25,000 | $25.04 | $626.0K | 265-99% |
| Oct 7, 2022 | Katkin Keith | Sell | 29,899 | $25.90 | $774.4K | 32,000-48% | |
| Oct 7, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 16,231 | $25.29 | $410.5K | 17,659-48% |
| Oct 4, 2022 | Katkin Keith | Sell | 4,101 | $25.06 | $102.8K | 32,000 | |
| Oct 4, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 33,769 | $25.02 | $844.9K | 17,659-66% |
| Sep 21, 2022 | Morrison Briggs | President, Head of R&D | Sell | 173,988 | $23.11 | $4.02M | 17,836-91% |
| Sep 16, 2022 | Morrison Briggs | President, Head of R&D | Sell | 279,420 | $23.64 | $6.60M | 17,836-94% |
| Sep 16, 2022 | Podlesak Dennis | Sell | 78,815 | $24.08 | $1.90M | 75,763-51% | |
| Aug 26, 2022 | Ordentlich Peter | Chief Scientific Officer | Sell | 25,000 | $25.04 | $625.9K | 265-99% |
| Aug 9, 2022 | Legault Pierre | Sell | 24,000 | $23.02 | $552.4K | 32,000-43% | |
| Jul 27, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 31,602 | $21.06 | $665.4K | 17,659-64% |
| Jul 8, 2022 | Metzger Michael A | Chief Executive Officer | Sell | 15,109 | $21.07 | $318.4K | 17,659-46% |
| Jul 5, 2022 | Morrison Briggs | President, Head of R&D | Sell | 62,292 | $19.00 | $1.18M | 17,836-78% |
| Apr 5, 2022 | Morrison Briggs | President, Head of R&D | Sell | 104,173 | $17.48 | $1.82M | 42,336-71% |
| Feb 3, 2022 | Nolte Alexander | Chief Accounting Officer | Sell | 968 | $16.65 | $16.1K | 0Exit |
| Feb 3, 2022 | Ordentlich Peter | Chief Scientific Officer | Sell | 1,412 | $16.65 | $23.5K | 0Exit |
SNDX Insiders
Similar Stocks to SNDX
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B